Related Experiment Video
Updated: Jan 10, 2026
Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
Empirical Antifungal Therapy Improves Survival in Patients With Acute-on-Chronic Liver Failure With Suspected
Nipun Verma1, Arun Valsan2, Pratibha Garg1
1Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh.
Introduction:
Invasive fungal infections (IFIs) in acute-on-chronic liver failure (ACLF) are associated with transplant delistings, high morbidity, and mortality. An optimal strategy of antifungal therapy in this setting remains uncertain. We compared suspicion-based (empirical) with investigation-driven (diagnostic/biomarker-driven-pre-emptive) antifungal therapy among patients with ACLF in a high-burden setting.
Methods:
In this parallel-group, pragmatic, randomized trial with blinded endpoint adjudication (NCT04157465), 216 hospitalized ACLF patients with predefined host and clinical factors for IFI were randomized (1:1) to empirical antifungal therapy at enrolment or diagnostic/biomarker-driven-pre-emptive therapy on laboratory, radiological, or mycological confirmation. Biomarker-guided and culture-guided antifungal stewardship protocols were implemented in both groups. The primary outcome was 28-day overall survival. Secondary outcomes included in-hospital mortality, changes in severity scores, adverse events, and cost-effectiveness. Heterogeneous treatment effects were explored through causal tree analysis.
Results:
Empirical antifungal therapy significantly improved 28-day survival compared with diagnostic/biomarker-driven-pre-emptive therapy (35% vs 13%; hazard ratio: 0.64, 95% confidence interval: 0.47-0.88; P = 0.005). Treatment success (37.4% vs 16.9%; P = 0.002) and IFI resolution (45.8% vs 22.5%, P = 0.001) were higher; in-hospital and IFI-attributable mortality (55.6% vs 75.9%; P = 0.003) was lower in the empirical group. Fewer adverse events with greater quality-of-life years gains (29.9 vs 10.1) and an incremental cost-effectiveness ratio of international normalized ratio 1,42,737 were observed with empirical therapy. The survival benefit was maximum among patients aged 40 years or older with cardiovascular failure but without respiratory failure.
Discussion:
Early empirical antifungal therapy within a structured stewardship framework improves survival in patients with ACLF and IFIs. Timely recognition, rapid diagnostics, and individualized antifungal strategies are essential to bridge these high-risk patients toward recovery or definitive therapies.
Insights
Early empirical antifungal therapy significantly improves survival in acute-on-chronic liver failure (ACLF) patients with invasive fungal infections (IFIs). This approach enhances treatment success and reduces mortality compared to delayed, diagnosis-driven strategies.
Area of Science:
- Hepatology
- Infectious Diseases
- Critical Care Medicine
Background:
- Invasive fungal infections (IFIs) pose a significant threat to patients with acute-on-chronic liver failure (ACLF), leading to transplant de-listing, high morbidity, and mortality.
- The optimal antifungal therapy strategy for ACLF patients remains uncertain, particularly in high-burden settings.
Purpose of the Study:
- To compare the efficacy and outcomes of suspicion-based (empirical) versus investigation-driven (diagnostic/biomarker-driven-pre-emptive) antifungal therapy in hospitalized ACLF patients at risk for IFIs.
Main Methods:
- A parallel-group, pragmatic, randomized trial (NCT04157465) involving 216 ACLF patients.
- Patients were randomized to receive either empirical antifungal therapy at enrollment or diagnostic/biomarker-driven-pre-emptive therapy upon confirmation.
- The primary outcome was 28-day overall survival, with secondary outcomes including mortality, severity scores, adverse events, and cost-effectiveness.
Main Results:
- Empirical antifungal therapy significantly improved 28-day survival (35% vs. 13%; p=0.005) compared to the diagnostic approach.
- Treatment success (37.4% vs. 16.9%; p=0.002) and IFI-resolution (45.8% vs. 22.5%; p=0.001) were higher with empirical therapy.
- Empirical therapy also led to lower in-hospital mortality (55.6% vs. 75.9%; p=0.003), fewer adverse events, and greater quality-adjusted life years (QALYs).
Conclusions:
- Early empirical antifungal therapy, integrated within a structured stewardship framework, enhances survival in ACLF patients with IFIs.
- Timely recognition, rapid diagnostics, and individualized antifungal strategies are crucial for improving outcomes in this high-risk population.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test